Annual change in pulmonary function and clinical characteristics of combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis: Over a 3-year follow-up

Tuberculosis and Respiratory Diseases

Volumn 77, Issue 1, 2014, Pages 18-23

  Kim, Yu Jin ^a   Shin, Seong Hyun ^a   Park, Jeong Woong ^a   Kyung, Sun Young ^a   Kang, Shin Myung ^a   Lee, Sang Pyo ^a   Sung, Yon Mi ^a   Kim, Yoon Kyung ^a   Jeong, Sung Hwan ^a  

^a Gachon University   (South Korea)

Author keywords

Idiopathic pulmonary fibrosis; Pulmonary emphysema; Pulmonary fibrosis; Respiratory function tests

Indexed keywords

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON MONOXIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; PREDNISOLONE; THEOPHYLLINE;

AGED; ARTICLE; CLINICAL ARTICLE; COMBINED PULMONARY FIBROSIS AND EMPHYSEMA; COMORBIDITY; CONTROLLED STUDY; COUGHING; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; LABORATORY TEST; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION TEST; MALE; PNEUMONIA; RETROSPECTIVE STUDY;

EID: 84906318288     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2014.77.1.18     Document Type: Article

References (20)

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
2. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-93. (Pubitemid 41448654)
3. Mura M, Zompatori M, Pacilli AM, Fasano L, Schiavina M, Fabbri M. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir Care 2006;51:257-65. (Pubitemid 46888402)
4. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012;141:222-31.
5. Grubstein A, Bendayan D, Schactman I, Cohen M, Shitrit D, Kramer MR. Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respir Med 2005;99:948-54. (Pubitemid 40796537)
6. Kurashima K, Takayanagi N, Tsuchiya N, Kanauchi T, Ueda M, Hoshi T, et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 2010;15:843-8.
7. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. (Pubitemid 37088595)
8. Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 2010;188:365-73.
9. Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 2010;15:265-71.
10. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011;38:176-83.
11. Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009;103:1209-15.
12. Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-5.
13. Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 2011;16:326-31.
14. Lim TK. Respiratory failure from combined emphysema and pulmonary fibrosis. Singapore Med J 1993;34:169-71.
15. Kitaguchi Y, Fujimoto K, Hayashi R, Hanaoka M, Honda T, Kubo K. Annual changes in pulmonary function in combined pulmonary fibrosis and emphysema: over a 5-year follow-up. Respir Med 2013;107:1986-92.
16. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
17. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013;144:234-40.
18. Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V, Incalzi RA. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr 2011;53:190-5.
19. Tkacova R, Kluchova Z, Joppa P, Petrasova D, Molcanyiova A. Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD. Respir Med 2007;101:1670-6. (Pubitemid 46930714)
20. Mura M, Belmonte G, Fanti S, Contini P, Pacilli AM, Fasano L, et al. Inflammatory activity is still present in the advanced stages of idiopathic pulmonary fibrosis. Respirology 2005;10:609-14. (Pubitemid 44944457)